

From: [DHCS PRIME](#)
Subject: PRIME Metrics 2.1.4 and 3.2.4
Date: Friday, June 7, 2019 10:36:28 AM
Attachments: [PPL-19-003 DY 14 3.2.4 Trending Break.pdf](#)

Dear PRIME Entities,

DHCS is providing notification of the two PRIME metric developments outlined below.

The 3.2.4 – *Use of Imaging Studies for Low Back Pain (anytime)* benchmarks for DY14 have been established using PRIME Entities’ DY13 Year End (YE) measurement data reported to DHCS during the DY14 Mid-Year (MY) reporting period, per PPL 19-003 (attached). To determine Achievement Values and payment, using DY13 YE data reported with DY14 specs as baseline, these benchmarks have been applied to DY14 MY performance and will be applied to DY14 YE performance. The benchmarks are identified below.

| DY14 Metric 3.2.4 Benchmarks | 25th | 90th |
|---|------------------------|------------------------|
| Appropriate | 0.38 | 0.61 |
| Inappropriate | 0.5 | 0.3 |

DHCS has made a decision to remove metric 2.1.4 – *Total Products Transfused*, from PRIME starting DY15 (July 1, 2019 through June 30, 2020). The decision to remove this PRIME measure was made in order to best align with the Maternal Data Center (MDC) Advisory Committee’s efforts to highlight transfusion measures that are most useful for hospital quality improvement activities. Entities must still report on this metric for DY14 YE reporting. In DY15, the number of metrics within Project 2.1 will reduce by 1, and impacted entities’ DY15 funding will be allocated to the remaining metrics within Domain 2 (DPHs) or across all PRIME Projects (DMPHs). This measure - *Total Products Transfused* - will continue to display in the MDC PRIME display through March 31, 2020. After that, it will be removed from the MDC display. If you have any further questions regarding the MDC PRIME display, feel free to email datacenter@cmqcc.org.

FYI: A policy letter regarding 2.7.5 is still forthcoming as mentioned in *PPL-19-004 Early Use DY15 Specifications*

If you have any questions on this email, please contact your PRIME liaison.

Thank you,

The PRIME Team

